Table 1.
• Formulation: intravitreal injection |
• Dose: 2 mg in 0.05 mL |
• Dosing: every month for 3 months and then every 2 months |
Pharmacokinetics |
• Time to peak intraocular concentration: immediately following dose |
• Volume of distribution: 4 mL |
• Half-life: 4.6 days |
Pharmacodynamics |
• Targets: VEGFA-D, PIGF |
• Effect: prevents VEGF receptor activation and stimulation of the angiogenesis cascade |
PIGF placental growth factor, VEGF vascular endothelial growth factor